Royalty Pharma's recent activities have been marked by significant movement and notable fluctuations across various aspects. Investment groups such as Evergreen Capital Management LLC, Panagora Asset Management Inc., and Cutter Capital Management LP have reduced their holdings in Royalty Pharma, while American Century Companies Inc., OMERS ADMINISTRATION Corp, and Ieq Capital LLC have increased theirs. Royalty Pharma’s stock prices have hit multiple 52-week highs due to robust growth.
They recently announced a $950 million royalties deal with Amgen for its lung cancer drug and have also reportedly secured major financing across three long-term tranches in a $2 billion debt offering. The company also raised its guidance and expanded its royalty interest with $885 million. Nevertheless, uncertainties involving the firm's Q2 revenue led to a rating downgrade by Wall Street Zen, though there was also an upgrade at one point. The firm has made strategic acquisitions and its activities are heavily skewed towards the confirmation of buy ratings.
Royalty Pharma Stocks News Analytics from Wed, 12 Feb 2025 08:00:00 GMT to Sat, 06 Sep 2025 20:10:31 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -6
